Reviews on recent clinical trials最新文献

{"title":"Immunoinformatics Approach for Optimization of Targeted Vaccine Design: New Paradigm in Clinical Trials and Healthcare Management.","authors":"Virendra S Gomase, Rupali Sharma, Suchita P Dhamane","doi":"10.2174/0115748871374235250702065617","DOIUrl":"10.2174/0115748871374235250702065617","url":null,"abstract":"<p><strong>Introduction: </strong>The immunoinformatics approach combines bioinformatics and computational tools, offering a revolutionary method for improving vaccine development by analyzing immune responses at the molecular level. Immunoinformatics enables the creation of customized vaccines designed for specific infections or cancer cells.</p><p><strong>Objective: </strong>The primary objective of immunoinformatics is to enhance the vaccine development process by predicting and boosting the body's immune response. It aims to identify potential immunogenic epitopes and biomarkers that are important for creating vaccines with greater specificity and efficacy, especially when dealing with large-scale data.</p><p><strong>Methods: </strong>Immunoinformatics utilizes a combination of proteomic, genomic, and epigenomic data, as well as machine learning algorithms and artificial intelligence techniques. These tools predict how various immunological components, e.g., T-cell and B-cell epitopes, interact with the immune system. This approach allows researchers to avoid traditional trial-and-error methods, enabling the efficient identification of potential vaccine candidates. Additionally, personalized vaccines can be developed by considering individual genetic and immunological characteristics.</p><p><strong>Results: </strong>The use of immunoinformatics techniques accelerates the screening of vaccine candidates, enhances patient stratification, and optimizes formulations for clinical trials. This approach has been shown to improve vaccine safety, efficacy, and development speed. It also holds promise for managing healthcare on a large scale by producing vaccines tailored to specific populations, thereby improving the overall effectiveness of vaccination programs.</p><p><strong>Conclusion: </strong>Immunoinformatics represents a transformative approach to vaccine research, improving clinical trial efficiency and enabling the development of more reliable, flexible, and personalized vaccines. This approach has the potential to significantly enhance global healthcare outcomes by accelerating the vaccine development process and optimizing vaccination strategies.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"89-115"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Review of Clinical Trial Regulations in Different Countries: Current Scenario and Future Prospect.","authors":"Mansi Sharma, Manan Grover, Shubham J Suryavanshi, Navneet Sharma, Vikesh Kumar Shukla","doi":"10.2174/0115748871365320250529125930","DOIUrl":"10.2174/0115748871365320250529125930","url":null,"abstract":"<p><strong>Introduction: </strong>Clinical trial regulations are essential for ensuring the safety, efficacy, and ethical conduct of drug development. However, the regulatory frameworks governing these trials vary significantly across different countries, affecting approval processes, trial conduct, and drug development timelines. By comparing clinical trial regulations and trial management practices, this study aims to identify regulatory challenges and propose improvements to enhance global harmonization.</p><p><strong>Methods: </strong>This review examines clinical trial regulations across the United States, European Union, Australia, and India, selected based on their diverse regulatory frameworks and global influence on clinical research. Literature screening was conducted using PubMed, Scopus, and official regulatory agency websites, focusing on publications from 2016 to 2024. Selection criteria included regulatory frameworks, amendments, ethical guidelines, and compliance measures related to clinical trials. The analysis covered key aspects such as trial approval timelines, safety reporting requirements, cost implications, and oversight mechanisms to identify regulatory challenges and potential improvements.</p><p><strong>Results: </strong>The findings reveal that although the studied countries maintain strict regulatory frameworks, they still exhibit gaps and inconsistencies. For instance, variations in approval timelines, safety reporting standards, and oversight mechanisms create inefficiencies and delays in drug development. It notes the absence of specific regulations for Clinical Research Organizations (CROs) authorization and herbal medicine trials in most regions.</p><p><strong>Discussion: </strong>Therefore, a key recommendation is to certify CROs to enhance the credibility of clinical trials. Additionally, specific regulations for herbal medicine trials are required to ensure safety and efficacy. Ethical concerns, particularly in pediatric and orphan drug research, demand more stringent oversight. The integration of blockchain technology is also proposed to improve accountability in drug development. Overall, promoting global regulatory harmonization is essential to minimize delays in patient access to essential therapies. These insights are intended to guide policymakers, researchers, and stakeholders in enhancing the quality, safety, and accessibility of medicines.</p><p><strong>Conclusion: </strong>This review underscores the importance of consistent, transparent, and adaptable clinical trial regulations across global jurisdictions. While current frameworks demonstrate a commitment to ethical and scientific rigor, targeted reforms, such as CRO recognition, herbal trial regulation, and technology integration, are important for advancing clinical research. A harmonized regulatory landscape not only accelerates drug development but also ensures timely patient access to innovative and life-saving therapies.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"e15748871365320"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144286363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Topical Application of Olive Oil in Preventing Pressure Injuries Among Hospitalized Patients with Mobility Limitations: A Cluster Randomized Trial in the United Arab Emirates.","authors":"Maraim Mohammed Saeed Almesmari, Rose Ekama Ilesanmi, Mona Gamal Mohamed","doi":"10.2174/0115748871363994250624201929","DOIUrl":"10.2174/0115748871363994250624201929","url":null,"abstract":"<p><strong>Introduction: </strong>Pressure injuries (PIs) pose a significant threat to the safety of hospitalized, mobility-compromised patients globally. Olive oil has shown promising results in preventing PIs due to its high concentrations of monounsaturated fatty acids and phenol antioxidants, known for their anti-inflammatory and cell-protective properties. This study aimed to evaluate the effectiveness of topical olive oil combined with routine preventive interventions in reducing PI incidence.</p><p><strong>Methods: </strong>A single-blinded, cluster-randomized study was conducted among 80 hospitalized patients at risk of developing PIs. Participants were randomized into two clusters: the intervention group (IVG, n=40) received standard PI preventive care (skin assessment, repositioning, support surfaces) plus topical olive oil application for 7 consecutive days; the control group (CG, n=40) received only standard care. PI prevalence and Braden Scale scores were assessed at baseline and post-intervention (days 3-8). Data were analyzed using descriptive statistics and paired sample t-tests.</p><p><strong>Results: </strong>At baseline, both groups had a PI prevalence of 52.5% (n=21). After the intervention, prevalence reduced to 5% (n=2) in IVG and 22.5% (n=9) in CG. The Braden Scale score in the IVG declined from 12.45±0.50 to 11.75±1.13. Statistically significant improvements were observed in Braden scores between day 1 and day 3 (IVG: x̄= -0.28±0.55, t= -3.14, p <0.05; CG: x̄= -0.58±4.69, t= -4.66, p <0.05) and between day 1 and day 8 (IVG: x̄= -0.70±1.07, t= -4.15, p <0.05; CG: x̄= 1.38±1.58, t= -5.50, p <0.05).</p><p><strong>Discussion: </strong>The findings underscore the clinical benefit of incorporating topical olive oil into standard PI preventive care. The significant reduction in PI prevalence and improved Braden Scale scores suggest olive oil's potential role as a protective agent due to its anti-inflammatory and antioxidant properties. These results align with existing literature on natural oil-based interventions for skin integrity. However, limitations include the small sample size and short duration, warranting further large-scale studies.</p><p><strong>Conclusion: </strong>Topical olive oil, when used alongside standard care practices, significantly reduced the incidence of pressure injuries in hospitalized, at risk patients. This approach could serve as a cost-effective, natural adjunct to PI prevention protocols, particularly in resource-limited healthcare settings.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"e15748871363994"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144584708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Anti-MDA5 Antibodies in Rapidly Progressive Interstitial Lung Disease: A Case Report and Literature Review.","authors":"Vittorio Grosso, Francisca Bulai, Alice Cerato, Cristina Olivero, Irene Pratico, Eleonora Galli, Francesca Diana, Matteo Nicoletto, Alberto Grosso, Luigi La Via, Fulvio Pomero","doi":"10.2174/0115748871350269250507052714","DOIUrl":"10.2174/0115748871350269250507052714","url":null,"abstract":"<p><strong>Background: </strong>Anti-melanoma Differentiation-associated Gene 5 (aMDA5) antibody-associated Rapidly Progressive Interstitial Lung Disease (RP-ILD) is a rare and potentially fatal condition.</p><p><strong>Case presentation: </strong>This case report describes a 78-year-old male who presented with a 10-day history of fever, cough, and asthenia. Despite initial treatment for suspected atypical pneumonia, the clinical condition of the patient rapidly deteriorated, necessitating intensive care and mechanical ventilation. High-resolution CT scans revealed a progressive interstitial lung disease with pneumomediastinum. Autoimmunity blood tests revealed high-titer anti-MDA5 antibodies, leading to a diagnosis of anti-MDA5 RP-ILD. Despite aggressive immunosuppressive therapy, the patient's condition continued to worsen, resulting in death. Our case underlines the importance of early recognition and diagnosis of anti-MDA5 RP-ILD, as it can present without typical dermatomyositis skin manifestations. The report also includes a comprehensive literature review covering the pathogenesis, clinical manifestations, diagnosis, and treatment options for anti-MDA5-associated disease.</p><p><strong>Conclusion: </strong>This case underscores the need for increased awareness of this condition among clinicians to improve early diagnosis and treatment outcomes.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"51-60"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144080038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination Vaccines: A Comprehensive Review of Pharmacokinetics, Pharmacodynamics, Regulatory Challenges, and Clinical Evidence.","authors":"Nisha Grewal, Smita Narwal, Gurvirender Singh, Dushyant, Ashwani K Dhingra, Monika Verma, Vishal Chanalia, Preeti Garg, Neha Yadav","doi":"10.2174/0115748871404248251013160024","DOIUrl":"10.2174/0115748871404248251013160024","url":null,"abstract":"<p><p>The primary function of a vaccine is to trigger a series of immune responses that are targeted at a specific pathogen. The present vaccine administration methods need to be improved, even though currently available immunisations are a remarkable success story in modern medicine and have significantly reduced global morbidity and mortality rates. Multiple immunisations were recently integrated into a single injection. This strategy is the most effective way to expedite immunisation administration and lessen the psychological burden associated with receiving multiple doses. However, safety is crucial for their widespread acceptance. Pharmacokinetics and pharmacodynamics of combination vaccination entail coordinated antigen delivery, immune activation, and effectiveness and safety. These vaccine combinations face regulatory approval of consistent manufacture, immunogenicity, and safety in various populations. Clinical studies and real-world research determine their safety and efficacy, guiding regulatory approval and post-launch monitoring. This review article discusses the pharmacokinetics and pharmacodynamics, regulatory concerns, and clinical evidence on the safety and effectiveness of combination vaccines.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"68-88"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145438905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Somatic Mutations Profiling in Genes Other than BRCA and TP53 Increasing Breast Carcinoma Risk Among Pakistani Patients.","authors":"Yasir Nawaz, Saba Munir, Fouzia Tanvir, Hafiza Fizzah Riaz, Aqeela Nawaz, Samreen Riaz","doi":"10.2174/0115748871370059250721143244","DOIUrl":"10.2174/0115748871370059250721143244","url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer is a very common disease affecting females on a global scale. It is responsible for approximately 10% of breast cancer-related fatalities. In 2022, approximately 2,308,897 new cases were reported globally. Recent studies focused on breast tumors have successfully recognized somatic mutations. This study aimed to identify previously unidentified somatic mutations in breast cancer patients belonging to Pakistan.</p><p><strong>Methods: </strong>The breast tumor sample was obtained from Jinnah Hospital, Lahore. The DNA was extracted, and whole-exome sequencing was conducted on six samples.</p><p><strong>Results: </strong>Gene mutations found include 58.69% synonymous SNV, 28.37% nonsynonymous SNV, 3.89% Frameshift deletion, 6.68% Nonframeshift deletion, 2.09% stopgain, and 0.28% stop loss. Among 39 genes analyzed, the prevalence of gene mutations varied, with HYDIN (100%), ENTHD1 (33.33%), ADRA1B (66.67%), GATA3 (50%), CDH1 (16.67%), RB1 (50%), MAP3K1 (100%), EGFR (50%), TRPM6 (33.33%), KHDRBS1 (33.33%), RBM25 (66.67%), SF3B3 (50%), TEK (16.67%), PGK2 (33.33%), CBFB (33.33%), ARID1A (66.67%), KMT2C (100%), HECTD1 (100%), LAMA3 (66.67%), FLG2 (83.33%), UGT2B4 (16.67%), STK33 (66.67%), ACP4 (50%), DNAH8 (100%), TNN (66.67%), IGSF3 (100%), TRIM67 (83.33%), DNMBP (100%), CORO7 (16.67%), CDC27 (33.33%), ZNF544 (50%), MST1 (16.67%), DENND2A (33.33%), NCKAP5 (50%), PCDHB10 (50%), FBXW7 (50%), EIF4G3 (66.67%), IL12RB2 (50%), and PDE4B (50%).</p><p><strong>Discussion: </strong>Breast cancer is a fatal disease. The high frequency of synonymous mutations was observed. The HYDIN, MAP3K1, KMT2C, HECTD1, DNAH8, IGSF3, DNMBP genes were 100% mutated then other genes.</p><p><strong>Conclusion: </strong>This study unveils new somatic alterations in different genes among early-onset Pakistani breast cancer patients, offering valuable insights for drug design targeting breast carcinoma.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"e15748871370059"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144776142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging Technology of Pharmaceutical Compliance: Role of Automation Tools in Regulatory Affairs for Clinical Trials.","authors":"Virendra S Gomase, Rupali Sharma, Satish Sardana","doi":"10.2174/0115748871366461250802092217","DOIUrl":"10.2174/0115748871366461250802092217","url":null,"abstract":"<p><strong>Background: </strong>The pharmaceutical industry operates within a complex regulatory environment, requiring strict compliance with global guidelines. Regulatory affairs (RA) departments are pivotal in ensuring drug approvals and compliance. However, the increasing complexity and volume of regulatory requirements have put a strain on traditional processes, driving the adoption of automation tools to streamline these operations.</p><p><strong>Objective: </strong>This review aims to explore the key automation tools used in regulatory affairs, focusing on their role in streamlining submissions, ensuring compliance, centralizing data, and reducing human error. It also aims to examine the emerging technologies in the field and their potential for enhancing automation.</p><p><strong>Methods: </strong>A comprehensive review of current automation tools in regulatory affairs was conducted. The key tools explored include Submission Management Systems (SMS), Regulatory Information Management (RIM) systems, Electronic Document Management Systems (EDMS), and Regulatory Intelligence Tools. Additionally, the role of emerging technologies like Artificial Intelligence (AI) and Machine Learning (ML) in automating regulatory processes was evaluated.</p><p><strong>Results: </strong>Automation tools such as SMS, RIM, EDMS, and Regulatory Intelligence Tools have been found to significantly improve the efficiency of regulatory affairs operations. These tools streamline submissions, centralize data, and ensure compliance. AI and ML technologies further enhance automation by enabling predictive analytics and automating risk assessments. Despite the advantages, challenges remain, including high implementation costs, data security concerns, and the need to adapt to varying global regulations. However, overcoming the challenges and limitations associated with these technologies in adopting regulatory automation is crucial.</p><p><strong>Discussion: </strong>This study highlights that automation tools are important for modernizing regulatory affairs by improving efficiency, accuracy, and compliance. The integration of Artificial Intelligence (AI) and Machine Learning (ML) adds predictive and adaptive capabilities, transforming static processes into dynamic systems. These technologies hold immense potential to reshape regulatory operations globally.</p><p><strong>Conclusion: </strong>Automation tools are becoming essential in the pharmaceutical industry to maintain regulatory compliance, reduce time-to-market, and manage the increasing complexity of drug development in a globalized industry. As emerging technologies like AI, ML, and blockchain continue to evolve, they promise to further revolutionize regulatory affairs processes.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"e15748871366461"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144966935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preface.","authors":"Ludovico Abenavoli","doi":"10.2174/0115748871474564260219074311","DOIUrl":"10.2174/0115748871474564260219074311","url":null,"abstract":"","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"vi"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147459557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cloud Computing Facilitating Data Storage, Collaboration, and Analysis in Global Healthcare Clinical Trials.","authors":"Virendra S Gomase, Arjun P Ghatule, Rupali Sharma, Satish Sardana, Suchita P Dhamane","doi":"10.2174/0115748871379249250701065507","DOIUrl":"10.2174/0115748871379249250701065507","url":null,"abstract":"<p><strong>Introduction: </strong>Healthcare data management, especially in the context of clinical trials, has been completely transformed by cloud computing. It makes it easier to store data, collaborate in real time, and perform advanced analytics across international research networks by providing scalable, secure, and affordable solutions. This paper explores how cloud computing is revolutionizing clinical trials, tackling issues including data integration, accessibility, and regulatory compliance.</p><p><strong>Materials and methods: </strong>Key factors assessed include cloud platform-enabled analytical tools, collaborative features, and data storage capacity. To ensure the safe management of sensitive healthcare data, adherence to laws like GDPR and HIPAA was emphasized.</p><p><strong>Results: </strong>Real-time updates and integration of multicenter trial data were made possible by cloud systems, which also showed notable gains in collaborative workflows and data sharing. High scalability storage options reduced infrastructure expenses while upholding security requirements. Rapid interpretation of complicated datasets was made possible by sophisticated analytical tools driven by machine learning and artificial intelligence, which expedited decision-making. Improved patient recruitment tactics and flexible trial designs are noteworthy examples.</p><p><strong>Conclusion: </strong>Cloud computing has become essential for international clinical trials because it provides unmatched efficiency in data analysis, communication, and storage. It is a pillar of contemporary healthcare research due to its capacity to guarantee data security and regulatory compliance as well as its creative analytical capabilities. Subsequent research ought to concentrate on further refining cloud solutions to tackle new issues and utilizing their complete capabilities in clinical trial administration.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"e15748871379249"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144675573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal Cancer Screening Modalities Among Saudi Population: Significant Predictors.","authors":"Mohammad Bukhetan Alharbi","doi":"10.2174/0115748871335743250417103659","DOIUrl":"10.2174/0115748871335743250417103659","url":null,"abstract":"<p><strong>Introduction: </strong>Understanding the public perception of colorectal cancer screening is crucial since early diagnosis lowers mortality rates associated with this type of cancer.</p><p><strong>Methods: </strong>The purpose of this study was to determine the most popular technique for colorectal cancer screening in Saudi Arabia. From September 2021 to February 2022, a cross-sectional study on adult Saudi population was undertaken. Data were collected through a self-created survey distributed via an online platform.</p><p><strong>Results: </strong>Out of 10,781 participants analyzed, 5,612 were found suitable for evaluating preferences between colonoscopy and fecal immunochemical test (FIT) as screening modalities. It was found that gender, employment, and age were important predictors for the preferred screening modality.</p><p><strong>Discussion: </strong>The patient's perspective on screening modalities is crucial to consider in national colorectal cancer screening programs. The future outlook for home-based fecal immunochemical Tests (FIT) may provide superior research regarding cost-effectiveness and adherence among patients compared to colonoscopy or medical facilities in FIT investigations.</p><p><strong>Conclusion: </strong>More attention should be paid to the population's preferred method of colorectal cancer screening, which could increase the success of the screening effort. Cultural and socioeconomic status might affect the generalizability of the study.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":"44-50"},"PeriodicalIF":1.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13539581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144143264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}